ERBB3 and pancreatic ductal adenocarcinoma: A few of these recurrent neoantigens are from known oncogenic drivers, for example, PIK3CA, MAPK1, ERBB2, ERBB3, and also from the KRAS G12D mutation, which we recently identified as a promising recurrent neoantigen-based immunotherapy target in pancreatic ductal adenocarcinoma (30).